{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T11:10:57Z","timestamp":1775473857268,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,6]]},"DOI":"10.7759\/cureus.106506","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T10:05:34Z","timestamp":1775469934000},"source":"Crossref","is-referenced-by-count":0,"title":["Dapagliflozin-Based Therapies in Patients With Type 2 Diabetes Mellitus in an Outpatient Real-World Setting Across India: The DAPATURN Study"],"prefix":"10.7759","author":[{"given":"Rajeev","family":"Chawla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabeer","family":"T. K.","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. P.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashwani","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mounam","family":"Chattopadhyay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaushik  M","family":"Rakshit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil","family":"Motiramani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajeev","family":"Philip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amber  C","family":"Shinde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sowmiya M","family":"K.","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santosh","family":"Revenkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamlesh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4103\/ajm.ajm_53_20","article-title":"Pathophysiology of diabetes: an overview","volume":"10","author":"Banday MZ","year":"2020","unstructured":"Banday MZ, Sameer AS, Nissar S. Pathophysiology of diabetes: an overview. Avicenna J Med. 2020, 10:174-88. 10.4103\/ajm.ajm_53_20","journal-title":"Avicenna J Med"},{"key":"ref2","unstructured":"International diabetes federation. Facts and figures. (2025). Accessed. November 12, 2025: https:\/\/idf.org\/about-diabetes\/diabetes-facts-figures\/."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/414782a","article-title":"Global and societal implications of the diabetes epidemic","volume":"414","author":"Zimmet P","year":"2001","unstructured":"Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001, 414:782-7. 10.1038\/414782a","journal-title":"Nature"},{"key":"ref4","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases. Risk factors for Type 2 diabetes. (2025). Accessed. November 12, 2025: https:\/\/www.niddk.nihDr..gov\/health-information\/diabetes\/overview\/risk-factors-type-2-diabetes."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1143067","article-title":"Microvascular and macrovascular complications of type 2 diabetes mellitus: Exome wide association analyses","volume":"14","author":"Mansour A","year":"2023","unstructured":"Mansour A, Mousa M, Abdelmannan D, Tay G, Hassoun A, Alsafar H. Microvascular and macrovascular complications of type 2 diabetes mellitus: Exome wide association analyses. Front Endocrinol (Lausanne). 2023, 14:1143067. 10.3389\/fendo.2023.1143067","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-017-0301-4","article-title":"Relation between different measures of glycemic exposure and microvascular and macrovascular complications in patients with type 2 diabetes mellitus: an observational cohort study","volume":"8","author":"van Wijngaarden RP","year":"2017","unstructured":"van Wijngaarden RP, Overbeek JA, Heintjes EM, et al.. Relation between different measures of glycemic exposure and microvascular and macrovascular complications in patients with type 2 diabetes mellitus: an observational cohort study. Diabetes Ther. 2017, 8:1097-109. 10.1007\/s13300-017-0301-4","journal-title":"Diabetes Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1850","article-title":"Impact of glucose level on micro- and macrovascular disease in the general population: a Mendelian randomization study","volume":"43","author":"Emanuelsson F","year":"2020","unstructured":"Emanuelsson F, Marott S, Tybj\u00e6rg-Hansen A, Nordestgaard BG, Benn M. Impact of glucose level on micro- and macrovascular disease in the general population: a Mendelian randomization study. Diabetes Care. 2020, 43:894-902. 10.2337\/dc19-1850","journal-title":"Diabetes Care"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1159\/000511002","article-title":"Management of type 2 diabetes: current strategies, unfocussed aspects, challenges, and alternatives","volume":"30","author":"Borse SP","year":"2021","unstructured":"Borse SP, Chhipa AS, Sharma V, Singh DP, Nivsarkar M. Management of type 2 diabetes: current strategies, unfocussed aspects, challenges, and alternatives. Med Princ Pract. 2021, 30:109-21. 10.1159\/000511002","journal-title":"Med Princ Pract"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2021.100725","article-title":"Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes","volume":"33","author":"Benham JL","year":"2021","unstructured":"Benham JL, Booth JE, Sigal RJ, Daskalopoulou SS, Leung AA, Rabi DM. Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes. Int J Cardiol Heart Vasc. 2021, 33:100725. 10.1016\/j.ijcha.2021.100725","journal-title":"Int J Cardiol Heart Vasc"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01148-3","article-title":"Dapagliflozin: a review in type 2 diabetes","volume":"79","author":"Dhillon S","year":"2019","unstructured":"Dhillon S. Dapagliflozin: a review in type 2 diabetes. Drugs. 2019, 79:1135-46. 10.1007\/s40265-019-01148-3","journal-title":"Drugs"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvad114.868","article-title":"FRI649 ADMIRE: assessing dapagliflozin and metformin as an initial regimen in diabetes mellitus for enhanced glucose control","volume":"7","author":"Phadke DU","year":"2023","unstructured":"Phadke DU, Gopal DJ, Biswas DK, Birla DA, Prasad A, Joshi P. FRI649 ADMIRE: assessing dapagliflozin and metformin as an initial regimen in diabetes mellitus for enhanced glucose control. J Endocr Soc. 2023, 7:10.1210\/jendso\/bvad114.868","journal-title":"J Endocr Soc"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.9998","article-title":"Use and effectiveness of dapagliflozin in patients with type 2 diabetes mellitus: a multicenter retrospective study in Taiwan","volume":"8","author":"Chen JF","year":"2020","unstructured":"Chen JF, Peng YS, Chen CS, et al.. Use and effectiveness of dapagliflozin in patients with type 2 diabetes mellitus: a multicenter retrospective study in Taiwan. PeerJ. 2020, 8:e9998. 10.7717\/peerj.9998","journal-title":"PeerJ"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_458_22","article-title":"Prescribing pattern of anti-diabetic drugs and adherence to the American Diabetes Association's (ADA) 2021 treatment guidelines among patients of type 2 diabetes mellitus: a cross-sectional study","volume":"11","author":"Tiwari K","year":"2022","unstructured":"Tiwari K, Bisht M, Kant R, Handu SS. Prescribing pattern of anti-diabetic drugs and adherence to the American Diabetes Association's (ADA) 2021 treatment guidelines among patients of type 2 diabetes mellitus: a cross-sectional study. J Family Med Prim Care. 2022, 11:6159-64. 10.4103\/jfmpc.jfmpc_458_22","journal-title":"J Family Med Prim Care"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1530\/endoabs.90.EP1106","article-title":"Diabetes treatment with dapagliflozin and its combinations: Insights from clinical practice","volume":"90","author":"Mehta A","year":"2023","unstructured":"Mehta A, Bafna A, Goel S, et al.. Diabetes treatment with dapagliflozin and its combinations: Insights from clinical practice. Endocrine Abstracts. 2023, 90:10.1530\/endoabs.90.EP1106","journal-title":"Endocrine Abstracts"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-022-01219-x","article-title":"Expert opinion: optimum clinical approach to combination-use of SGLT2i + DPP4i in the Indian diabetes setting","volume":"13","author":"Chadha M","year":"2022","unstructured":"Chadha M, Das AK, Deb P, et al.. Expert opinion: optimum clinical approach to combination-use of SGLT2i + DPP4i in the Indian diabetes setting. Diabetes Ther. 2022, 13:1097-114. 10.1007\/s13300-022-01219-x","journal-title":"Diabetes Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.74820","article-title":"Clinical profile, comorbidities and therapies in type 2 diabetes patients on Sitagliptin-based therapy in Indian outpatient setting","volume":"16","author":"Bhat KA","year":"2024","unstructured":"Bhat KA, Singh KP, Maddukuri HR, et al.. Clinical profile, comorbidities and therapies in type 2 diabetes patients on Sitagliptin-based therapy in Indian outpatient setting. Cureus. 2024, 16:e74820. 10.7759\/cureus.74820","journal-title":"Cureus"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-0467","article-title":"Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study","volume":"37","author":"Jabbour SA","year":"2014","unstructured":"Jabbour SA, Hardy E, Sugg J, Parikh S. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care. 2014, 37:740-50. 10.2337\/dc13-0467","journal-title":"Diabetes Care"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/461928-dapagliflozin-based-therapies-in-patients-with-type-2-diabetes-mellitus-in-an-outpatient-real-world-setting-across-india-the-dapaturn-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T10:05:41Z","timestamp":1775469941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/461928-dapagliflozin-based-therapies-in-patients-with-type-2-diabetes-mellitus-in-an-outpatient-real-world-setting-across-india-the-dapaturn-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.106506","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,6]]}}}